US Pharma MarketingFDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment
MSD has received approval from the FDA for both Keytruda and Keytruda Qlex, in combination with Welireg, as an adjuvant treatment for adults with renal ccRCC. The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients. The estimated 24-month DFS rate was 81% with Keytruda plus Welireg and 74% with Keytruda plus placebo. Credit: Sai Thaw Kyar / Shutterstock.com. Merck & Co (MSD) has received approval from the US Food and Drug Administration (FDA) for both Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), in combination with Welireg (belzutifan), as adjuvant treatment…
MSD has received approval from the FDA for both Keytruda and Keytruda Qlex, in combination with Welireg, as an adjuvant treatment for adults with renal ccRCC.
Source: Pharmaceutical Technology